Moving to an Allogeneic RNA Cell Therapy Program with Cartesian Therapeutics' Dr. Metin Kurtoglu

<p>Dr. Metin Kurtoglu, COO at Cartesian Therapeutics, explains the clinical-stage biotech&apos;s autologous RNA cell therapies, Descartes-08 for Myasthenia Gravis and Descartes-11 for multiple myeloma. He also explains Descartes-25, their allogeneic RNA cell therapy and the reasons for the move to &quot;off-the-shelf,&quot; and why the future of RNA cell therapy is not confined to rare and fatal diseases. We also discuss post-care for patients having received infusions.</p>